Dr. Reddy's Laboratories Ltd (RDY) 44.10 $RDY New Strong

New Post Public Reply Private Reply Replies (0) Message Board

Aug 3, 2016 at 12:02 AM

Dr. Reddy's Laboratories Ltd (RDY) 44.10 $RDY

New Strong Sell Stocks for July 28th
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:57AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
OSB: 24.48 (-0.96), FCH: 6.29 (unch), WFC: 47.70 (-0.11), RDY: 44.10 (-0.40), WAB: 68.06 (-0.40)

Downgrade Alert for Dr Reddys Laboratories (RDY)
Comtex SmarTrend(R) - Thu Jul 28, 3:46AM CDT
Dr Reddys Laboratories (NYSE:RDY) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $43.82 on volume of 801,000 shares, above average daily volume of 303,000. In the past 52 weeks, Dr Reddys Laboratories share prices have been bracketed by a low of $40.68 and a high of $68.00 and closed yesterday at $43.82, 8% above that low price. Over the past week, the 200-day moving average (MA) has gone down 0.7% while the 50-day MA has remained constant.
RDY: 44.10 (-0.40)

Dr. Reddy's (RDY) Q1 Earnings and Revenues Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:10AM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2017 earnings per American Depositary Share of 11 cents, down 79.6% from the year-ago quarter.
RDY: 44.10 (-0.40), BMY: 75.05 (-1.14)

Dr Reddys Laboratories Falls 15.57% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 26, 2:01PM CDT
Dr Reddys Laboratories (NYSE:RDY) traded in a range yesterday that spanned from a low of $43.70 to a high of $49.07. Yesterday, the shares fell 15.6%, which took the trading range below the 3-day low of $51.72 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RDY: 44.10 (-0.40)

Dr. Reddy's Q1 FY17 Financial Results
BusinessWire - Tue Jul 26, 1:03PM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY):
RDY: 44.10 (-0.40)

Dr. Reddy's Laboratories Announces the Launch of Omeprazole and Sodium bicarbonate Capsules in the U.S. Market
BusinessWire - Mon Jul 18, 1:43AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID(R) (omeprazole/sodium bicarbonate) capsules in the United States market, having been approved by the U.S. Food & Drug Administration (USFDA).
RDY: 44.10 (-0.40)

Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
Arpita Dutt - Zacks Investment Research - Thu Jul 14, 7:10AM CDT
Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
AGN: 250.75 (-4.11), MYL: 46.53 (-0.21), TEVA: 52.96 (-0.65), RDY: 44.10 (-0.40)

Looking For Generic Drug Stocks? Pick Up These Winners
Zacks Premium Research - Zacks Investment Research - Wed Jul 13, 5:27PM CDT
The short term earnings outlook for these stocks have been building momentum recently, so don't miss out!
MYL: 46.53 (-0.21), RDY: 44.10 (-0.40), AMPH: 16.17 (-0.12)

Dr. Reddy's to acquire product portfolio from TEVA for US Market
BusinessWire - Sat Jun 11, 8:26AM CDT
Dr. Reddy's Laboratories (BSE:500124, NSE

RREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the U.S. Federal Trade Commission of Dr. Reddy's as a buyer.
AGN: 250.75 (-4.11), RDY: 44.10 (-0.40)

Promius Pharma Launches Sernivo(TM) (betamethasone dipropionate) Spray, 0.05%
BusinessWire - Wed Jun 01, 1:48AM CDT
Dr. Reddy's Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo(TM) (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
RDY: 44.10 (-0.40)

Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 45.07 (-0.22), JNJ: 124.85 (-0.55), RDY: 44.10 (-0.40)

Dr. Reddy's Enters the Branded Consumer Health Arena Through the Acquisition of Six OTC Brands
BusinessWire - Wed May 25, 5:47AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN'S(R), BUFFERIN(R), NUPERCAINAL(R) Ointment, CRUEX(R) Nail Gel, COMTREX(R), and MYOFLEX(R).
RDY: 44.10 (-0.40)

Dr. Reddy's Q4 and FY16 Financial Results
BusinessWire - Thu May 12, 5:47AM CDT
--Q4 EBITDA at Rs. 4.8 billion(12.8% of the revenues)
RDY: 44.10 (-0.40)

Dr. Reddy's Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the Board of the Company
BusinessWire - Wed May 11, 12:14PM CDT
Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11, 2016.
RDY: 44.10 (-0.40)

Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 124.85 (-0.55), GILD: 79.57 (-0.89), PFE: 36.39 (-0.92), AMGN: 174.15 (-0.01), ABBV: 66.78 (-0.16), RDY: 44.10 (-0.40), AVXS: 34.90 (-0.70), NVS: 82.96 (-0.11)

Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May 12, 6.30 PM IST / 9.00 AM EDT
BusinessWire - Tue Apr 26, 6:34AM CDT
Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 44.10 (-0.40)

ZEMBRACE(TM) SymTouch(TM) (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the Acute Treatment of Migraine with or without Aura in Adults, is Now Commercially Available in the U.S.
BusinessWire - Tue Apr 19, 4:12AM CDT
Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouchis now commercially available in the U.S.
RDY: 44.10 (-0.40)

Cutispharma, Dr. Reddy's Laboratories Announce Partnership
PR Newswire - Tue Apr 05, 5:00AM CDT
CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy's Laboratories Ltd. to advance several programs in CutisPharma's R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
RDY: 44.10 (-0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Arrvel's Thermal Printers: Aiming at E-Com Sellers

Arrvel's Thermal Printing Push: An Overview No one would have pegged tiny thermal label printers as game-changers, but here we are. Arrvel's new lineup of thermal printers is shaking up the world for anyone who's ever had to slap on a shipping label or get inventory organized. They're targeting e-commerce folks and small businesses, which sounds like the right move as...

Retail Trading Platforms Report Record Growth in 2026

A Boom in Self-Directed Investing Times are changing, folks. More people than ever are taking finance into their own hands, wielding smartphones like fiscal swords in the name of self-directed investment. No middlemen, no fancy office, just straight-up trading from wherever you might be perched. Four major platforms now boast over 41 million funded accounts combined, each...

Young Visionaries Win Junior Medals at STARMUS VIII

Fresh from the Canary Islands' shores, STARMUS VIII has lifted the veil on two young powerhouses shaping tomorrow—Valeria Corrales and Aneeshwar Kunchala. These two have snagged coveted honors, crowning them as champions of their generation. Igniting Passion for Science and the Environment Valeria Corrales isn't just another face in the crowd; she’s the force behind a...

APsystems Unveils C&I Storage Solutions at SEF 2026

APsystems Puts the Spotlight on Advanced Storage Move over, traditional energy solutions—APsystems is stepping into the future with a bang at the Smart Energy Forum 2026 in Prague. Set your sights on the latest advancements in solar and energy storage solutions as the company unveils its comprehensive offerings. If you’re hanging around the PVA EXPO PRAHA on October...

Kexing Biopharm Expands Global Reach at CPHI Milan

Kexing Biopharm's Showstopper Moment in Milan Call it a strategic blowout or just audacious timing—Kexing Biopharm's move at the CPHI Milan 2026 has painted a clear picture. From October 6th to 8th, Milan was the stage where Kexing rolled out its showcase, bragging about a pipeline that screams innovation and possibility. And let’s be honest, their timing couldn’t...

RingConn Smart Ring Gains Key FDA 510(k) Clearance

FDA Clearance: A Major Step for RingConn In a space where every tiny gadget-maker is desperately clawing for a regulatory nod, RingConn—a venture born from Shenzhen Ninenovo Technology Limited—has snagged an FDA 510(k) clearance (Clearance No. K260490) for their wearable Smart Ring that measures blood oxygen levels non-invasively. October 10, 2026, marked the day when...

AI in Music: CITY JAM Focuses on Human Creativity

Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...

CenterPoint Deploys Crews for Hurricane Aid Relief

CenterPoint’s Commitment Amidst Crisis Now, when a hurricane slams into the coast, it’s go time for everyone in the game. CenterPoint Energy, never one to sit on the sidelines, is showing up with a hefty squad to help fix the mess left by Hurricane Isaias. A robust 355-strong team is heading out to assist with power restoration down there in Florida. This isn’t just...

Tchah Sup Kim: A Retrospective at KCCNY in 2026

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...

Jiangxi Dialogues: Youths Forge Global Ties in 2026

Bringing Global Youth to the Table In the heart of Jiangxi, China, young minds from across the globe gathered not just to chat but to shape the future. A bunch who only a decade ago might have been ignored in such circles are now leading discussions, and they’ve kicked off their powwow on September 22, 2026, with a bang in Nanchang. What’s the Agenda? Imagine more...